Who
Louis W. Sullivan
Director
Company insider
Files Form 4 as: Director, United Therapeutics; Director, Emergent BioSolutions; Director, Henry Schein; Director, ANI Pharmaceuticals; Director, Inhibitex; Director, Cigna; Director, 3m; Director, Bristol-Myers Squibb.
In numbers
- Trades disclosed
- 372
- Buys
- 2
- Sells
- 36
- Bought
- $44K
- Sold
- $49.1M
- Companies
- 8
- Companies where not an officer
- 8
- First trade
- 30 Dec 2005
- Last trade
- 22 Jul 2026
- Last filed
- 23 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jul 2026filed 23 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,380 at $0.00 | filing |
| 22 Jul 2026filed 23 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,380 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | —650 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —650 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —650 at $0.00 | filing |
| 9 Jul 2026filed 13 Jul 2026 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | —650 at $0.00 | filing |
| 22 Dec 2025filed 23 Dec 2025 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,230 at $0.00 | filing |
| 22 Dec 2025filed 23 Dec 2025 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,720 at $0.00 | filing |
| 22 Dec 2025filed 23 Dec 2025 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | $594K3,230 at $183.98 | filing |
| 22 Dec 2025filed 23 Dec 2025 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | $625K2,720 at $229.81 | filing |
| 22 Dec 2025filed 23 Dec 2025 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $556K1,087 at $511.22 | filing |
| 22 Dec 2025filed 23 Dec 2025 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.5M4,863 at $512.34 | filing |
| 25 Jul 2025filed 28 Jul 2025 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —590 at $0.00 | filing |
| 25 Jul 2025filed 28 Jul 2025 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code M | —590 at $0.00 | filing |
| 24 Jul 2025filed 28 Jul 2025 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —650 at $0.00 | filing |
| 24 Jul 2025filed 28 Jul 2025 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,830 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | EBS Emergent BioSolutionsoption or derivative · Biotechnology | SEC FORM 4 Code A | —15,824 at $0.00 | filing |
| 30 Apr 2025filed 2 May 2025 | EBS Emergent BioSolutionsBiotechnology | SEC FORM 4 Code A | —34,403 at $0.00 | filing |
| 19 Dec 2024filed 19 Dec 2024 | UTHR United TherapeuticsBiotechnology | SEC FORM 4 Code G | —1,851 at $0.00 | filing |
| 18 Dec 2024filed 19 Dec 2024 | UTHR United Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
News
Contrasting Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR)UTHR · dailypolitical.com · 18 Oct 2026United Therapeutics (NASDAQ: UTHR) general counsel sells 8,300 shares under planUTHR · themarketsdaily.com · 17 Oct 2026Head to Head Survey: Xenon Pharmaceuticals (NASDAQ:XENE) vs. United Therapeutics (NASDAQ:UTHR)UTHR · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Louis W. Sullivan; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.